

Haematologica
HAEMATOL/2019/225375
Version 3

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma

Elisabet E. Manasanch, Jatin J. Shah, Hans C. Lee, Donna M. Weber, Sheeba K. Thomas, Behrang Amini, Jasper Olsem, Brandon Crumpton, Ashley Morphey, Zuzana Berkova, Lei Feng, and Robert Z. Orlowski

Disclosures: E. Manasanch has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, Merck; consultant fees from Takeda, Celgene, and Sanofi. J. Shah is currently employed by Karyopharm Therapeutics. H. Lee has received consulting fees from Adaptive Biotechnologies, Celgene, Pimera and Takeda and research support from Amgen, Daiichi Sankyo, Janssen and Takeda. D. Weber reports no conflicts of interest. S. Thomas has received consulting fees from Amgen and research support from Acerta Pharma, Amgen, Array BioPharma, Bristol-Myers-Squibb, Celgene and Idera. B. Amini reports no conflicts of interest. J. Olsem reports no conflicts of interest. B. Crumpton reports no conflicts of interest. A. Morphey reports no conflicts of interest. L. Feng reports no conflicts of interest. Z. Berkova reports no conflicts of interest. R. Orlowski has received consulting fees from Amgen, Bristol-Myers-Squibb, Celgene, GSK Biologicals, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, and Takeda and research support from BioTheryX.

Contributions: EM treated patients, interpreted the data, and wrote the paper. JS designed the research, treated patients and interpreted the data. JO, BC and AM included patients on the study and interpreted the data. HL, DW, BA, ST treated patients and interpreted the data. LF analyzed the data. ZB interpreted the data and wrote the paper. RZO designed the research, treated patients, and provided manuscript comments.